Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions

Corso, Christopher D.; Bindra, Ranjit S.

doi:10.1016/j.semradonc.2016.06.003

Cited by 25 publications

(32 citation statements)

References 217 publications

(235 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, multiple antibody-based therapies targeting either the cytotoxic T-lymphocyte associated pathway (CTLA-4) or the programmed death receptor (PD-1) axis have been FDA-approved for the treatment of a variety of cancers, and are in clinical trials for additional cancer applications [219][220][221] .…”

Section: Checkpoint Blockade In Cancer Immunotherapymentioning

confidence: 99%

“…Glioblastoma multiforme (GBM) is an aggressive brain tumor that accounts for 67% of all primary brain tumors 220 . Due to the highly invasive nature of the disease, cancer cells often lie beyond the visible tumor boundary, which makes full surgical resection difficult 297 .…”

Section: Introductionmentioning

confidence: 99%

“…90% of patients develop tumor recurrence at or near the surgical site and many tumors develop drug resistance 136 . Despite advances in drug development, the five year survival rate for GBM is 12% and has remained virtually unchanged over the past decade 220 .…”

Section: Introductionmentioning

confidence: 99%

“…Cis-diamminedichloroplatinum (Cisplatin, CDDP), a powerful chemotherapeutic, has been effective as a first-line therapy for several types of cancer, including testicular, ovarian, bladder and lung cancers 220 , and has also been used as an adjuvant in the treatment of pediatric brain tumors 298 . However, adult GBM patients treated with CDDP suffered severe nephron-and neurotoxicity even at sub-therapeutic drug concentrations [299][300][301] .…”

Section: Introductionmentioning

confidence: 99%

“…Biodegradable nanoparticle formulations can shield healthy tissues from the toxic effects of CDDP, especially during systemic administration, while enhancing therapeutic efficacy 220,303 . When combined with a strategy to increase the NP concentration at the target site, this drug delivery approach provides the ability to achieve sustained therapeutic CDDP levels in the tumor while minimizing both systemic and local off-target effects.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Ultrasound-Based Therapies for the Treatment of Cancer

Timbie

View full text Add to dashboard Cite

Section: Checkpoint Blockade In Cancer Immunotherapymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Ultrasound-Based Therapies for the Treatment of Cancer

Timbie

View full text Add to dashboard Cite

Metabolic changes in glioblastomas in response to choline kinase inhibition: In vivo MRS in rodent models

et al. 2022

View full text Add to dashboard Cite

Changes in glioblastoma (GBM) metabolism was investigated in response to JAS239, a choline kinase inhibitor, using MRS. In addition to the inhibition of phosphocholine synthesis, we investigated changes in other key metabolic pathways associated with GBM progression and treatment response. Three syngeneic rodent models of GBM were used: F98 (N = 12) and 9L (N = 8) models in rats and GL261 (N = 10) in mice. Rodents were intracranially injected with GBM cells in the right cortex and tumor growth was monitored using T2‐weighted images. Animals were treated once daily with intraperitoneal injections of 4 mg/kg JAS239 (F98 rats, n = 6; 9L rats, n = 6; GL261 mice, n = 5) or saline (control group, F98 rats, n = 6; 9L rats, n = 2; GL261 mice, n = 5) for five consecutive days. Single voxel spectra were acquired on Days 0 (T0, baseline) and 6 (T6, end of treatment) from the tumor as well as the contralateral normal brain using a PRESS sequence. Changes in metabolite ratios (tCho/tCr, tCho/NAA, mI/tCr, Glx/tCr and (Lip + Lac)/Cr) were used to assess metabolic pathway alterations in response to JAS239. Tumor growth arrest was noted in all models in response to JAS239 treatment compared with saline‐treated animals, with a significant reduction (p < 0.05) in the F98 model. A reduction in tCho/tCr was observed with JAS239 treatment in all GBM models, indicating reduced phospholipid metabolism, with the highest reduction in 9L followed by GL261 and F98 tumors. A significant reduction (p < 0.05) in the tCho/NAA ratio was observed in the 9L model. A significant reduction in mI/tCr (p < 0.05) was found in JAS239‐treated F98 tumors compared with the saline‐treated animals. A non‐significant trend of reduction in Glx/tCr was observed only in F98 and 9L tumors. JAS239‐treated F98 tumors also showed a significant increase in Lip + Lac (p < 0.05), indicating increased cell death. This study demonstrated the utility of MRS in assessing metabolic changes in GBM in response to choline kinase inhibition.

show abstract

On glioblastoma and the search for a cure: where do we stand?

Bianco

Bastiancich

Jankovski

et al. 2017

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Although brain tumours have been documented and recorded since the nineteenth century, 2016 marked 90 years since Percival Bailey and Harvey Cushing coined the term "glioblastoma multiforme". Since that time, although extensive developments in diagnosis and treatment have been made, relatively little improvement on prognosis has been achieved. The resilience of GBM thus makes treating this tumour one of the biggest challenges currently faced by neuro-oncology. Aggressive and robust development, coupled with difficulties of complete resection, drug delivery and therapeutic resistance to treatment are some of the main issues that this nemesis presents today. Current treatments are far from satisfactory with poor prognosis, and focus on palliative management rather than curative intervention. However, therapeutic research leading to developments in novel treatment stratagems show promise in combating this disease. Here we present a review on GBM, looking at the history and advances which have shaped neurosurgery over the last century that cumulate to the present day management of GBM, while also exploring future perspectives in treatment options that could lead to new treatments on the road to a cure.

show abstract

Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions

Cited by 25 publications

References 217 publications

Ultrasound-Based Therapies for the Treatment of Cancer

Ultrasound-Based Therapies for the Treatment of Cancer

Metabolic changes in glioblastomas in response to choline kinase inhibition: In vivo MRS in rodent models

On glioblastoma and the search for a cure: where do we stand?

Contact Info

Product

Resources

About